Breast Cancer Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Hormonal Therapy, Targeted Therapy, and Surgery), Region And Segment Forecasts, 2023-2031.

Report ID : 1069 | Published : 2023-06-17 | Pages: 140 | Format: PDF/EXCEL

The Breast Cancer Market is expected to grow at an 8.5 % CAGR during the forecast period for 2023-2031.

Breast Cancer Market

Breast cancer start when cells in the breast begin to grow out of control. These cells form tumour that can often see on an x-ray. Breast cancer is the most common cancer among women, after skin cancer and second leading cause of cancer death in women after lung cancer. Breast cancer is broadly classified into two include non-invasive and invasive breast cancer. Ductal carcinoma in situ (DCIS) is non-invasive cancer of milk duct cells. Invasive breast cancer is divided into two types, invasive ductal carcinoma, and invasive lobular carcinoma. Invasive ductal carcinoma, also called infiltrating ductal carcinoma and it consists of about 50-75 percent of all breast cancer. Invasive breast cancer that spreads to other parts of the body is called metastatic breast cancer. All non-invasive and invasive breast cancer tested for hormone (oestrogen and progesterone) receptors. The hormone receptor-positive cancer can be treated with hormone therapy such as tamoxifen and an aromatase inhibitor. Breast cancer is the most common cancer in women both in developed and developing countries. Breast cancer is most common in U.S. women, with about 252,710 new cases diagnosed and 40,610 die in 2017. Almost 81% of breast cancer are diagnosed among women age 50 years and older, and 89% of breast cancer deaths occur in this age group.

Diagnosis of breast cancer can be done with physical examination, clinical breast examination (CBE), mammogram, ultrasound exam, MRI (magnetic resonance imaging), blood test, and biopsy. There are different types of treatment for patients with breast cancer include surgery, chemotherapy, hormone therapy, and targeted therapy. Surgery such as breast-conserving surgery, total mastectomy, modified radical mastectomy. Systemic chemotherapy is used in the treatment of breast cancer includes capecitabine (Xeloda), docetaxel (Taxotere), eribulin (Halaven), gemcitabine (Gemzar), paclitaxel (Taxol), vinorelbine (Navelbine), and others. Hormone therapy with a luteinizing hormone-releasing hormone (LHRH) agonist is given to premenopausal who have been diagnosed with hormone receptor-positive breast cancer. Targeted therapy used in breast cancer include trastuzumab, pertuzumab, ado-trastuzumab emtansine, lapatinib, neratinib, palbociclib, ribociclib and abemaciclib.

The diagnosis, staging, and treatment of patients with breast cancer require multidisciplinary care in an acute hospital setting. In the U.S. Genentech Access to Care Foundation (GATCF) scheme helping patients to have access to Herceptin. Genentech Access to Care Foundation (GATCF) scheme helps people who don’t have health insurance coverage and those who have health insurance but have trouble paying for Herceptin. Additionally, Medicare insurance policies pay the fee for a clinical breast examination (CBE) once every two years for women at average risk of breast cancer.

Competitive Landscape

Some of The Key Players in The Breast Cancer Market:

  • Novartis AG
  • Genentech, Inc
  • GlaxoSmithKline plc
  • Mylan Pharmaceuticals Inc
  • Teva Pharmaceuticals USA, Inc
  • AstraZeneca
  • Apotex Corp
  • Breckenridge Pharmaceutical, Inc
  • Pfizer Inc.
  • Alvogen
  • Other Prominent Players

The Breast Cancer Market Report Scope

Report Attribute


Growth Rate CAGR

CAGR of 8.5 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year


Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Treatment

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Novartis AG, Genentech, Inc., GlaxoSmithKline plc, Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., AstraZeneca, Apotex Corp. Breckenridge Pharmaceutical, Inc., Pfizer Inc., Alvogen, and others

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.


Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Breast Cancer Market Snapshot

Chapter 4. Global Breast Cancer Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Treatment Estimates & Trend Analysis

5.1. By Treatment & Market Share, 2022 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Treatment:

5.2.1. Chemotherapy

5.2.2. Targeted Therapy

5.2.3. Hormonal Therapy

5.2.4. Surgery

Chapter 6. Breast Cancer Market Segmentation 2: Regional Estimates & Trend Analysis

6.1. North America

6.1.1. North America Breast Cancer Market revenue (US$ Million) estimates and forecasts By Treatment, 2022 - 2030

6.1.2. North America Breast Cancer Market revenue (US$ Million) estimates and forecasts by country, 2022 - 2030

6.2. Europe

6.2.1. Europe Breast Cancer Market revenue (US$ Million) By Treatment, 2022 - 2030

6.2.2. Europe Breast Cancer Market revenue (US$ Million) by country, 2022 - 2030 

6.3. Asia Pacific

6.3.1. Asia Pacific Breast Cancer Market revenue (US$ Million) By Treatment, 2022 - 2030

6.3.2. Asia Pacific Breast Cancer Market revenue (US$ Million) by country, 2022 - 2030

6.4. Latin America

6.4.1. Latin America Breast Cancer Market revenue (US$ Million) By Treatment, (US$ Million)

6.4.2. Latin America Breast Cancer Market revenue (US$ Million) by country, (US$ Million) 2022 - 2030 

6.5. Middle East & Africa

6.5.1. Middle East & Africa Breast Cancer Market revenue (US$ Million) By Treatment, (US$ Million)

6.5.2. Middle East & Africa Breast Cancer Market revenue (US$ Million) by country, (US$ Million) 2022 - 2030

Chapter 7. Competitive Landscape

7.1. Major Mergers and Acquisitions/Strategic Alliances

7.2. Company Profiles

7.2.1. Novartis AG

7.2.2. Genentech, Inc

7.2.3. GlaxoSmithKline plc

7.2.4. Mylan Pharmaceuticals Inc

7.2.5. Teva Pharmaceuticals USA, Inc

7.2.6. AstraZeneca

7.2.7. Apotex Corp

7.2.8. Breckenridge Pharmaceutical, Inc

7.2.9. Pfizer Inc.

7.2.10. Alvogen

7.2.11. Other Key Players

Global Breast Cancer Market Segmentation

Global Breast Cancer Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Treatment

  • Chemotherapy
  • Targeted Therapy
  • Hormonal Therapy
  • Surgery

Breast Cancer Market

Global Breast Cancer Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Region

  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • North America
    • S.
    • Canada
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Australia & New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa


InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

What is the Breast Cancer Market Growth?

Novartis AG, Genentech, Inc., GlaxoSmithKline plc, Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., AstraZeneca, Apotex Corp. Breckenridge

Our Clients

Media Citations

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
Get a Custom Report
Contact us with a specific research request.

Kindly share us with a topic or product segment or objectives to meet your strategy goals

Review Request

We’ll review your request & send a personalized quote for cost and time needed

Final Delivery

Sit back while our team work on your research. We will send bi-monthly updates and discuss our finding on a conference call upon final delivery..